Corrigendum: Sjögren’s, renal tubular acidosis and osteomalacia - An Asian Indian series (The Open Rheumatology Journal, (2014), 8, (103-109), 10.2174/1874312901408010103);Sjögren’s, renal tubular acidosis and osteomalacia - An Asian Indian series

Open Rheumatology Journal

Volumn 8, Issue 1, 2014, Pages 103-109

  Sandhya, Pulukool ^a   Danda, Debashish ^a   Rajaratnam, Simon ^a   Thomas, Nihal ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Osteomalacia; Pseudofractures; Renal Tubular Acidosis; Sj gren s syndrome; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLATE MOFETIL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD PH; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHLOREMIA; HYPERCHLOREMIC METABOLIC ACIDOSIS; HYPOKALEMIC PERIODIC PARALYSIS; HYPOTHYROIDISM; KIDNEY CALCIFICATION; KIDNEY TUBULE ACIDOSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; NEPHROLITHIASIS; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; URINE PH; VITAMIN BLOOD LEVEL;

EID: 84928882512     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901812010114     Document Type: Erratum

References (30)

1. [1] Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87: 210-9.
2. [2] Sánchez-Guerrero J, Pérez-Dosal MR, Cárdenas-Velázquez F, et al. Prevalence of Sjögren’s syndrome in ambulatory patients according to the American-European Consensus Group criteria. Rheumatology (Oxford) 2005; 44: 235-240.
3. [3] Goules AV, Tatouli IP, Moutsopoulos HM, et al. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013; 65: 2945-53.
4. [4] Pokorny G, Sonkodi S, Iványi B, et al. Renal involvement in patients with primary Sjögren’s syndrome. Scand J Rheumatol 1989; 18: 231-4.
5. [5] Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant 2001; 16: 2328-36.
6. [6] Bridoux F, Kyndt X, Abou-Ayache R, et al. Proximal tubular dysfunction in primary Sjögren's syndrome: A clinicopathological study of 2 cases. Clin Nephrol 2004; 61: 434-9.
7. [7] Yang YS, Peng CH, Sia SK, et al. Acquired hypophosphatemia osteomalacia associated with Fanconi's syndrome in Sjögren's syndrome. Rheumatol Int 2007; 27: 593-7.
8. [8] Díaz Rodríguez C, González Rivero C, Trinidad San José JC, et al. Osteal complications as first manifestation in a patient with primary Sjögren's Syndrome and with associated distal tubular acidosis (type 1) and chronic renal insufficiency. Ther Apher Dial 2004; 8: 160-3.
9. [9] Pal B, Griffiths ID. Primary Sjögren's syndrome presenting as osteomalacia secondary to renal tubular acidosis. Br J Clin Pract 1988; 42: 436-8.
10. [10] Hajjaj-Hassouni N, Guedira N, Lazrak N, et al. Osteomalacia as a presenting manifestation of Sjögren's syndrome (abstract). Rev Rhum Engl Ed 1995; 62: 529-32.
11. [11] Okazaki H, Muto S, Kanai N, et al. A case of primary Sjögren's syndrome presenting as osteomalacia secondary to renal tubular acidosis (abstract). Ryumachi 1991; 31: 45-53.
12. [12] Okada M, Suzuki K, Hidaka T, et al. Rapid improvement of osteomalacia by treatment in case with sjögren's syndrome, rheumatoid arthritis and renal tubular acidosis type 1. Intern Med 2001; 40: 829-32.
13. [13] Fulop M, Mackay M. Renal tubular acidosis, Sjögren's syndrome, and bone disease. Arch Intern Med 2004; 164: 905-9.
14. [14] Marquez-Julio A, Rapoport A, Wilansky DL, et al. Purpura associated with hypergammaglobulinemia, renal tubular acidosis and osteomalacia. Can Med Assoc J 1977; 116: 53-8.
15. [15] Khandelwal D, Bhattacharya S, Gadodia A, et al. Metabolic bone disease as a presenting manifestation of primary Sjögren's syndrome: Three cases and review of literature. Indian J Endocrinol Metab 2011; 15(4): 341-5.
16. [16] Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjo¨gren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group (review). Ann Rheum Dis 2002; 61: 554-558.
17. [17] Shiboski SC, Shiboski CH, Criswell L, et al. Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475-87.
18. [18] Fox RI, Robinson CA, Curd JG, et al. Sjögren’s syndrome: proposed criteria for classification. Arthritis Rheum 1986; 29: 577-85.
19. [19] Chen W, Chen Y, Li A. The clinical and pathological manifestations of aristolochic acid nephropathy--the report of 58 cases. Zhonghua Yi Xue Za Zhi 2001; 81: 1101-5. (Chinese)
20. [20] Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome (review). Arch Intern Med 2004; 164: 1275-84.
21. [21] Ren H, Wang WM, Chen XN, et al. Renal involvement and followup of 130 patients with primary Sjögren's syndrome. J Rheumatol 2008; 35: 278-84.
22. [22] Rao N, John M, Thomas N, et al. Aetiological, clinical and metabolic profile of hypokalemic periodic paralysis: A singlecentre experience. Natl Med J Ind 2006; 19: 246-249.
23. [23] Talal N, Zisman E, Schur PH. Renal tubular acidosis, glomerulonephritis and immunologic factors in Sjögren's syndrome. Arthritis Rheum 1968; 11: 774-86.
24. [24] Aasarød K, Haga HJ, Berg KJ, et al. Renal involvement in primary Sjögren's syndrome. QJM 2000; 93: 297-304.
25. [25] Pertovaara M, Korpela M, Kouri T, et al. The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients. Rheumatology (Oxford) 1999; 38(11): 1113-20.
26. [26] Maripuri S, Grande JP, Osborn TG, et al. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 2009; 4: 1423-31.
27. [27] Thomas N, Banumathy R, Seshadri MS. Hypokalemic Periodic Paralysis: An unusual cause. J Assoc Phys Ind 1996; 44: 207-8.
28. [28] Shivane VK, Sarathi V, Bandgar T, et al. High prevalence of hypovitaminosis D in young healthy adults from the western part of India. Postgrad Med J 2011; 87: 514-8.
29. [29] Gopinath K, Danda D. Supplementation of 1, 25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis 2011; 14: 332-9.
30. [30] Ramachandiran N. Apparently persistent weakness after recurrent hypokalemic paralysis: a tale of two disorders. South Med J 2008; 101: 940-2.